AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05088356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan (50 mg/m2)
Study NCT05088356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 Reagent System
Description: The CliniMACS® CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations is manufactured by Miltenyi Biotec
Study NCT05088356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 4-6ng/mL
Study NCT05088356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 40mg/kg
Study NCT05088356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Dose 0.24 mg/kg, manufactured by Genzyme
Study NCT05088356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent
Description: Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL
Study NCT05088356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 10 mg/kg
Study NCT05088356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF 1000 mg BID
Study NCT05088356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 5 mg BID
Study NCT04676373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALGLUCOSIDASE ALFA
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study NCT06514235 — intervention group
Intervention type: OTHER
Intervention: Observational study (Non-interventional study)
Description: This is an observational study.
Study NCT05424120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual aspiration
Description: One option from standard of care
Study NCT05424120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wall suction
Description: One option from standard of care
Study NCT05424120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum bottle drainage
Description: One option from standard of care
Study NCT05396690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Injection [Byfavo]
Description: Induction dose: 6 mg/kg/h with sufentanil Maintenance dose: 1\~2 mg/kg/h with sufentanil If arousal occurs during surgery, rapidly increase the infusion rate of remimazolam to 12 mg/kg/h and infuse for 1 minute. If the patient's arousal persists after these measures, stop remimazolam infusion and replace with another drug.
Study NCT05396690 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Induction dose: 2\~3 mg midazolam with sufentanil Maintenance: Adjust the concentration to be BIS 35-65 based on 0.5 mac If arousal occurs during surgery, raise the concentration of sevoflurane to 1.5 MAC (increase the total gas flow rate to 8 l/min) and if arousal persists after 1 minute, administer midazolam 2-3 mg.
Study NCT05634291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care as prescribed by healthcare provider.
Study NCT05634291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nottingham AR smartphone app with active intervention
Description: AR software treatment delivered by smartphone app and developed by VRx Medical (VRx) using established principles of illusion therapies (e.g. mirror therapy) for pain management.
Study NCT06157437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Pulse field Ablation
Description: Bidirectional block of the cavo-tricuspid isthmus (CTI) was performed with the novel focal pulse field ablation.
Study NCT03243149 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: fMRI - GE Medical System
Description: Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.~The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy.
Study NCT03243149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI - GE Medical System
Description: Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.~The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy.
Study NCT03243149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI - GE Medical System
Description: Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.~The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy.
Study NCT04742218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Description: K-877 Tablet
Study NCT05282784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Patients will be treated with hyperthermia 2 or 3 times a week. Treatment will be performed for 1 hours per each visit.~Patients will be treated with radiotherapy 5 times a week.
Study NCT05282784 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Patients will be treated with radiotherapy 5 times a week.
Study NCT05282784 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients will be treated with radiotherapy 5 times a week.
Study NCT04459338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exendin-9,39
Description: Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor
Study NCT04459338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo comparator
Study NCT05269329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8, film-coated tablets, 20 mg/day
Description: 20 mg/day (1 tablet twice a day)
Study NCT05269329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8, film-coated tablets, 40 mg/day
Description: 40 mg/day (2 tablets twice a day)
Study NCT05269329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8, film-coated tablets, 80 mg/day
Description: 80 mg/day (4 tablets twice a day)
Study NCT05269329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1, 2, or 4 tablets twice a day
Study NCT05762575 — intervention group
Intervention type: OTHER
Intervention: knotting methods
Description: The volunteers in experimental group study new knotting technology.
Study NCT05236530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg (1 mL of 2 mg/mL oral solution) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
Study NCT05236530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Repaglinide 0.5 mg (1 x 0.5 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
Study NCT05236530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan 15 mg (10 mL of 7.5 mg/5 mL syrup) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
Study NCT05236530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg (1 x 500 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
Study NCT05236530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaplacide
Description: Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 4-probe cocktail co administered on the morning of Day 3.
Study NCT05236530 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lumefantrine
Description: Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
Study NCT05236530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
Study NCT05236530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir 50 mg (1 x 50 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
Study NCT05236530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaplacide
Description: Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 2-probe cocktail co administered on the morning of Day 3.
Study NCT05052905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LibraVR
Description: LibraVR is a standalone VR-based rehabilitation software for use in physiotherapy. It is designed to work with standard off-the-shelf hardware that is tested and approved for use in conjunction with the software.~LibraVR system consists of the software (LibraVR Clinic) running on a PC (database of patients, creation of protocols, uploading protocols to mobile), and the LibraVR Mobile APP that runs on commercial mobile smartphones embedded in a lightweight cardboard or plastic VR viewer that the child wears as they would eyeglasses. The software displays a range of immersive VR exercises.
Study NCT05551416 — intervention group
Intervention type: OTHER
Intervention: Identification of risk factors
Description: Demographics, life habits and risk factors studies
Study NCT05551416 — intervention group
Intervention type: OTHER
Intervention: Characterization of premalignant gastric lesions
Description: Identification and characterization of premalignant gastric lesions through high definition endoscopic study. Concordance between endoscopic and histological classifications
Study NCT05551416 — intervention group
Intervention type: OTHER
Intervention: Identification of biomarkers
Description: Multiomic studies
Study NCT05551416 — intervention group
Intervention type: OTHER
Intervention: Identification of gastric cancer hereditary predisposition
Description: Genomic studies for the identification of individuals with hereditary GC predisposition
Study NCT06351046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfullness Based Stress Reduction Program
Description: Online group class/week for eight consecutive weeks with 8 sessions
Study NCT06351046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Pain Self-management program
Description: The VRPS has a variety of modules that can be used for pain management. For this project we have selected relaxation, mindful escapes, pain distraction games, and dynamic breathing modules. All modules were designed to minimize triggers of emotional distress or cybersickness.
Study NCT05230901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).
Study NCT05230901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).
Study NCT05230901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg
Description: Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication .
Study NCT05230901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydralazine
Description: Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)
Study NCT06557681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Treadmill Training Group (VTT)
Description: The Virtual Reality-Treadmill Training Group (VTT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy followed by an additional 30 minutes of virtual reality-treadmill training. The sequence of these therapies can vary with each session. The virtual reality-treadmill training, conducted under the supervision of a therapist, will focus on five key components: precision stepping, obstacle negotiation, direction of progression, precision acceleration, and walking velocity. Evaluations of walking and balance abilities will be conducted before and after the intervention.
Study NCT06557681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy Group (CT)
Description: The Conventional Therapy Group (CT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy, aimed at improving walking and balance functions. The therapy will be administered by a therapist and may include exercises focused on muscle strength increase, gait training for step length and walking speed improvement, and balance training. Evaluations of walking and balance abilities will be conducted before and after the intervention.
Study NCT06412003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based balance training
Description: This is a family member supported home-based balance training program designed for community-dwelling people with MS to improve balance and walking abilities as well as cognitive functions. The intervention program aims to have participants with MS reach high-intensity balance tasks during the program. A bi-weekly two-on-one, semi-structured, video-chat session with participants and their exercise supporter and research team will be conducted using videoconferencing techniques (e.g., Zoom, Skype, or Facetime).
Study NCT04712461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUPPORTS
Description: The SUPPORTS implementation model will be developed and refined based on community feedback. It will likely include a combination of strategies demonstrated to reduce burnout and secondary traumatic stress in the occupational health literature, such as psychoeducation about burnout, mindfulness training, or changes in scheduling or the physical environment. As the most effective interventions have been shown to involve an integration of both individual- and organization-directed strategies supporting each other, SUPPORTS will aim to include both. For example, the model may include provider-directed strategies such as group peer consultation meetings, and organizational-directed strategies such as increasing communication and providers' involvement in organizational decisions. Through this approach, SUPPORTS will aim to target therapist burnout and turnover at the provider and organizational level.
Study NCT05207501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.
Study NCT05207501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.
Study NCT04909723 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NOV-001
Description: NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.
Study NCT04909723 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB1000S
Description: A recombinant live biotherapeutic product.
Study NCT04909723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB2000P
Description: A botanically derived polysaccharide.
Study NCT04909723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04796415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the DEMA-Pro intervention
Description: Trained DEMA-Pro coaches will deliver six weekly, 1-hour telephone sessions. The first session is an orientation to the DEMA-Pro intervention and development of the initial Weekly Activity Plan based on the patient's self-identified meaningful activity. Over the next five weekly sessions, the coach uses problem-solving strategies to facilitate dyad collaboration to mutually identify meaningful activities and make a realist plan to achieve the patient-identified meaning activity goals. In each session, the patient and caregiver also select, review, and discuss one of six topics in the Self-Management Toolkit (e.g., planning meaningful activities; learning strategies for living with subjective cognitive impairment; finding resources, planning for the future).
Study NCT06262867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready. Set. Food! Stage 1 Mix ins
Description: These supplements contain cow's milk, eggs, and peanuts.
Study NCT05303714 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX and PIPAC
Description: A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system.
Study NCT05303714 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFOX and PIPAC
Description: A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system.
Study NCT05887492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG260
Description: CoREST inhibitor, administered orally
Study NCT05887492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, an anti-PD-1 antibody, administered intravenously
Study NCT05612321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum application
Description: vacuum-assisted delivery
Study NCT05612321 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum application
Description: vacuum-assisted delivery
Study NCT06134388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.